Campus Alert: Find the latest UMMS campus news and resources at umassmed.edu/coronavirus

Page Menu

Kenneth L Rock

UMassMed Faculty Page

Inventions:

Title: T Cell Hybridomas Expressing Luciferase Under the Control of IL-2 Promotor Element. UMMS15-15; Patent Pending. 

  • T Cell Hybridomas Expressing Luciferase Under the Control of IL-2 Promotor Elements. 

Title: Use of Cathepsin B Inhibitors for the Treatment of IL-1 Related Diseases. UMMS08-51; Patent Pending.  

  • This innovation describes detailed mechanisms of how immune cells recognize microorganisms (non-self) from host (self). The cytoplasmic receptor complex NALP3 inflammasome has been found to react to a variety of crystals such as silica crystals or cholesterol crystals, all of which were found to require phagocytosis for activation. By inhibiting phagosomal acidification, the inventors were able to prevent activation of NALP3 in the presence of the crystal activators. Understanding these mechanisms may be valuable to research into IL-1 related diseases of sterile inflammation including atherlosclerosis, amyloidosis, Alzheimer silicosis, asbestosis and others. 

 

Innovation TopicsResearch ToolsGene expressionSmall MoleculesBiologicsIL-1 related diseases of sterile inflammationAtherosclerosisAmyolateral Sclerosis (ALS)Alzheimer's diseasesSilicosisAsbestosis